|
CN105348241A
|
|
Synthetic method of vorapaxar sulfate intermediate
|
|
CN105254628A
|
|
Pyrazolopyridine derivative anti-tumor compound and preparation method and application thereof
|
|
CN105111089A
|
|
Bixalomer intermediate
|
|
CN105061216A
|
|
Bixalomer intermediate preparing method
|
|
CN104860888A
|
|
Alcaftadine intermediate and synthetic method for alcaftadine
|
|
CN104817555A
|
|
M crystal form of solifenacin succinate and preparation method of M crystal form
|
|
CN104788438A
|
|
B crystal form of empagliflozin and preparation of B crystal form
|
|
CN104447763A
|
|
Biphenyl tetrazole compound
|
|
CN104496917A
|
|
Synthesis method of Favipiravir
|
|
CN104402892A
|
|
Angiotensin II antagonistic compound
|
|
CN104356056A
|
|
Preparation method of perampanel intermediate
|
|
CN104367550A
|
|
Belotecan long circulation nano liposome and preparation method thereof
|
|
CN104473873A
|
|
Cabazitaxel long-circulation liposome injection and preparation method thereof
|
|
CN104434931A
|
|
Compound oral solid preparation containing ticagrelor and aspirin and preparation method of solid preparation
|
|
CN104292214A
|
|
Synthesis method of efinaconazole and intermediate thereof
|
|
CN104274402A
|
|
Medicine water suspended emulsion containing rebamipide and preparation method of medicine water suspended emulsion
|
|
CN104326923A
|
|
Synthetic method of desvenlafaxine succinate
|
|
CN104288116A
|
|
Mirabegron sustained-release tablet composition
|
|
CN104163803A
|
|
Synthesis method of ceftaroline fosamil
|
|
CN103923066A
|
|
Multi-target anti-tumor compound and preparation method and application thereof
|
